Selected research
Market Structure
Global Teriparatide Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Teriparatide Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Teriparatide Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Teriparatide Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Teriparatide Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Teriparatide Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Teriparatide Injection include Shenzhen Salubris Pharmaceuticals Co., Ltd., Shanghai United Cell Biotechnology Co., Ltd., Pfenex Inc., Eli Lilly and Company and Alvogen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Teriparatide Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Teriparatide Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Teriparatide Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Teriparatide Injection market size, projected growth trends, production technologies, key applications, and end-use industries.
Teriparatide Injection Segment by Company
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Shanghai United Cell Biotechnology Co., Ltd.
Pfenex Inc.
Eli Lilly and Company
Alvogen
Teriparatide Injection Segment by Type
2.5ML
3.0ML
Teriparatide Injection Segment by Application
Hospital
Clinic
Others
Teriparatide Injection Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Teriparatide Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Teriparatide Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Teriparatide Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Teriparatide Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Teriparatide Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Teriparatide Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Teriparatide Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 2.5ML
- 3.0ML
Applications
- Hospital
- Clinic
- Others
Companies covered
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Shanghai United Cell Biotechnology Co., Ltd.
- Pfenex Inc.
- Eli Lilly and Company
- Alvogen
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Teriparatide Injection Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Teriparatide Injection Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Teriparatide Injection Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Teriparatide Injection Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Teriparatide Injection Market Dynamics
- 2.1 Teriparatide Injection Industry Trends
- 2.2 Teriparatide Injection Industry Drivers
- 2.3 Teriparatide Injection Industry Opportunities and Challenges
- 2.4 Teriparatide Injection Industry Restraints
3 Teriparatide Injection Market by Manufacturers
- 3.1 Global Teriparatide Injection Revenue by Manufacturers (2021-2026)
- 3.2 Global Teriparatide Injection Sales by Manufacturers (2021-2026)
- 3.3 Global Teriparatide Injection Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Teriparatide Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Teriparatide Injection Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Teriparatide Injection Manufacturers, Product Type & Application
- 3.7 Global Teriparatide Injection Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Teriparatide Injection Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Teriparatide Injection Players Market Share by Revenue in 2025
- 3.8.3 2025 Teriparatide Injection Tier 1, Tier 2, and Tier 3
4 Teriparatide Injection Market by Type
- 4.1 Teriparatide Injection Type Introduction
- 4.1.1 2.5ML
- 4.1.2 3.0ML
- 4.2 Global Teriparatide Injection Sales by Type
- 4.2.1 Global Teriparatide Injection Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Teriparatide Injection Sales by Type (2021-2032)
- 4.2.3 Global Teriparatide Injection Sales Market Share by Type (2021-2032)
- 4.3 Global Teriparatide Injection Revenue by Type
- 4.3.1 Global Teriparatide Injection Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Teriparatide Injection Revenue by Type (2021-2032)
- 4.3.3 Global Teriparatide Injection Revenue Market Share by Type (2021-2032)
5 Teriparatide Injection Market by Application
- 5.1 Teriparatide Injection Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Teriparatide Injection Sales by Application
- 5.2.1 Global Teriparatide Injection Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Teriparatide Injection Sales by Application (2021-2032)
- 5.2.3 Global Teriparatide Injection Sales Market Share by Application (2021-2032)
- 5.3 Global Teriparatide Injection Revenue by Application
- 5.3.1 Global Teriparatide Injection Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Teriparatide Injection Revenue by Application (2021-2032)
- 5.3.3 Global Teriparatide Injection Revenue Market Share by Application (2021-2032)
6 Global Teriparatide Injection Sales by Region
- 6.1 Global Teriparatide Injection Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Teriparatide Injection Sales by Region (2021-2032)
- 6.2.1 Global Teriparatide Injection Sales by Region (2021-2026)
- 6.2.2 Global Teriparatide Injection Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Teriparatide Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Teriparatide Injection Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Teriparatide Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Teriparatide Injection Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Teriparatide Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Teriparatide Injection Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Teriparatide Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Teriparatide Injection Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Teriparatide Injection Revenue by Region
- 7.1 Global Teriparatide Injection Revenue by Region
- 7.1.1 Global Teriparatide Injection Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Teriparatide Injection Revenue by Region (2021-2026)
- 7.1.3 Global Teriparatide Injection Revenue by Region (2027-2032)
- 7.1.4 Global Teriparatide Injection Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Teriparatide Injection Revenue (2021-2032)
- 7.2.2 North America Teriparatide Injection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Teriparatide Injection Revenue (2021-2032)
- 7.3.2 Europe Teriparatide Injection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Teriparatide Injection Revenue (2021-2032)
- 7.4.2 Asia-Pacific Teriparatide Injection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Teriparatide Injection Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Teriparatide Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Shenzhen Salubris Pharmaceuticals Co., Ltd.
- 8.1.1 Shenzhen Salubris Pharmaceuticals Co., Ltd. Company Information
- 8.1.2 Shenzhen Salubris Pharmaceuticals Co., Ltd. Business Overview
- 8.1.3 Shenzhen Salubris Pharmaceuticals Co., Ltd. Teriparatide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Shenzhen Salubris Pharmaceuticals Co., Ltd. Teriparatide Injection Product Portfolio
- 8.1.5 Shenzhen Salubris Pharmaceuticals Co., Ltd. Recent Developments
- 8.2 Shanghai United Cell Biotechnology Co., Ltd.
- 8.2.1 Shanghai United Cell Biotechnology Co., Ltd. Company Information
- 8.2.2 Shanghai United Cell Biotechnology Co., Ltd. Business Overview
- 8.2.3 Shanghai United Cell Biotechnology Co., Ltd. Teriparatide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Shanghai United Cell Biotechnology Co., Ltd. Teriparatide Injection Product Portfolio
- 8.2.5 Shanghai United Cell Biotechnology Co., Ltd. Recent Developments
- 8.3 Pfenex Inc.
- 8.3.1 Pfenex Inc. Company Information
- 8.3.2 Pfenex Inc. Business Overview
- 8.3.3 Pfenex Inc. Teriparatide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Pfenex Inc. Teriparatide Injection Product Portfolio
- 8.3.5 Pfenex Inc. Recent Developments
- 8.4 Eli Lilly and Company
- 8.4.1 Eli Lilly and Company Company Information
- 8.4.2 Eli Lilly and Company Business Overview
- 8.4.3 Eli Lilly and Company Teriparatide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Eli Lilly and Company Teriparatide Injection Product Portfolio
- 8.4.5 Eli Lilly and Company Recent Developments
- 8.5 Alvogen
- 8.5.1 Alvogen Company Information
- 8.5.2 Alvogen Business Overview
- 8.5.3 Alvogen Teriparatide Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Alvogen Teriparatide Injection Product Portfolio
- 8.5.5 Alvogen Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Teriparatide Injection Value Chain Analysis
- 9.1.1 Teriparatide Injection Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Teriparatide Injection Production Mode & Process
- 9.2 Teriparatide Injection Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Teriparatide Injection Distributors
- 9.2.3 Teriparatide Injection Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst